Search

Efgartigimod alfa

Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … [L43190] A formulation for subcutaneous use that combines efgartigimod alfa and hyaluronidase was later approved for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP

Ethyl hydroxybenzoate

Leflunomide

Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.

Clonazepam

Unfortunately, however, like most benzodiazepines, clonazepam use has also been associated with recreational use and drug abuse.[FDA Label][L5572,F3763,F3787,F3796] … Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year.

Amoxapine

In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. … In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood.

Dupilumab

[L7186,L7192,L41439] Dupilumab is currently under investigations for potential therapeutic use in diseases driven by allergic reactions or type 2 inflammation, such as pediatric atopic dermatitis, and … It was first approved by the FDA in 2017.

Bebtelovimab

in the US. … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.

Sibutramine

Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity.

Berotralstat

[L41960] In December 2025, the FDA expanded Berotralstat pediatric use with approval of an oral pellet formulation for prophylaxis in children with HAE aged 2 and older.[L54793,L54798] … [A225166] Berotralstat is strictly used to prevent, but not treat, these attacks.[L26656] Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules.

Ensulizole

It was demonstrated by studies that ensulizole treatment provided protection against cyclobutane pyrimidine dimers and photosensitized the formation of oxidized guanine bases after UV-A or UV-B exposure